Vidarbha News

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Market: Industry Analysis, Epidemiology, Treatment, Therapies and Key Companies by DelveInsight

 Breaking News
  • No posts were found

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Market: Industry Analysis, Epidemiology, Treatment, Therapies and Key Companies by DelveInsight

August 12
20:46 2021
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Market: Industry Analysis, Epidemiology, Treatment, Therapies and Key Companies by DelveInsight
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Market

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare entity grouped with the acute myeloid leukemia-related precursor neoplasms in the 2008 World Health Organization classification. It is a clinically aggressive tumor that often initially presents as cutaneous lesions and subsequently progresses to bone marrow involvement and leukemic dissemination characterized by enhanced expression of CD56, CD4, and CD123.

 

DelveInsight’s “Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), historical and forecasted epidemiology as well as the Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Some key facts of Blastic Plasmacytoid Dendritic Cell Neoplasm Market are:

  • The total incident population of BPDCN in 7MM countries was estimated to be 1,786 cases in 2017.
  • The market size of BPDCN in the seven major markets was found to be USD 17.79 million in 2017.
  • 90% of patients with BPDCN present with asymptomatic skin lesions – and early recognition can be challenging due to overlapping features with other benign and malignant disorders
  • More men than women are diagnosed with BPDCN (~3:1 ratio), and it is most common in patients age 60 years and older.
  • Drugs in the clinical trials are expected to propel the growth of the of Blastic Plasmacytoid Dendritic Cell Neoplasm drugs market in the upcoming years
  • Expected launch of UCART123 (Cellectis), IMGN632 (ImmunoGen), XmAb14045 (Xencor) etc. shall fuel the growth of the market during the forecast period i.e., 2020-2030.

 

Request for Sample Report: https://www.delveinsight.com/sample-request/blastic-plasmacytoid-dendritic-cell-neoplasm-bpdcn-market

 

BPDCN can be referred by different names such as blastic NK cell lymphoma, agranular CD4+ NK cell leukemia, blastic NK leukemia/lymphoma, and agranular CD4+ CD56+ hematodermic neoplasm. Also, as per WHO 2016 classification, BPDCN is currently classified as a distinct entity within the myeloid neoplasm and acute leukemia classification.

Common BPDCN symptoms include:

  • Deep purple skin lesions.
  • Fatigue.
  • Fever.
  • Night sweats.

 

Some of the BPCDN Companies are:

  • Immunogen
  • Cellectis
  • Xencor
  • MustangBio
  • And Many Others

 

Some of the Blastic Plasmacytoid Dendritic Cell Neoplasm Therapies are:

  • IMGN632
  • UCART123
  • MB 102
  • XmAb14045
  • And Many Others

 

Request for Sample Report: https://www.delveinsight.com/sample-request/blastic-plasmacytoid-dendritic-cell-neoplasm-bpdcn-market

 

Table of Contents:

1. Key Insights

2. Executive summary

3. Organizations

4. Epidemiology and Market Methodology

5. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): Market Overview at a Glance

6. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): Disease Overview

7. Epidemiology and Patient Population

8. Current Treatment Practices

9. Unmet Needs

10. Marketed drugs

11. Elzonris: Stemline Therapeutics

12. Emerging Therapies

13. Key Cross Competition

14. MB-102: Mustang Bio

15. IMGN632: ImmunoGen/ Jazz Pharmaceuticals

16. UniCAR02-T-CD123: Cellex Patient Treatment GmbH

17. Venetoclax: AbbVie

18. XmAb14045: Xencor

19. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): 7 Major Market Analysis

20. Seven Major Market Outlook

21. Total market size of Blastic plasmacytoid dendritic cell neoplasm in Japan

22. Total market size of Blastic plasmacytoid dendritic cell neoplasm by by Line of Therapies in Japan

23. Market Drivers

24. Market Barriers

25. SWOT Analysis

26. Reimbursement policies

27. Case Study

28. KOL Views

29. Appendix

30. Report Methodology

31. DelveInsight Capabilities

32. Disclaimer

33. About DelveInsight

34. Bibliography

 

Request for Detailed TOC: https://www.delveinsight.com/sample-request/blastic-plasmacytoid-dendritic-cell-neoplasm-bpdcn-market

 

About Delveinsight : 

DelveInsight Business Research is a leading Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.

Get hold of all the Pharma and healthcare market research reports on our market research subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/blastic-plasmacytoid-dendritic-cell-neoplasm-bpdcn-malignancy-market